Top Markets
#1 Black Phoenix Black Phoenix +355.13%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.86%
#4 OpenEden OpenEden +60.23%
#5 Akedo Akedo +56.95%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.51%
#9 Humanity Humanity +19.18%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Peringkat dalam Saham #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Harga Saham
$0.01292666
Terakhir disinkronkan: 2025-04-08
Kapitalisasi Pasar
$157.54K
Perubahan (1 hari)
6.84%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Synairgen plc (SNG)

Kategori

Healthcare
Rasio P/B untuk Synairgen plc (SNG)
Rasio P/B per August 2026 TTM: 0.15
Menurut laporan keuangan dan harga saham terbaru dari Synairgen plc, rasio P/B saat ini (TTM) adalah 0.15. Pada akhir 2022, rasio P/B perusahaan adalah 0.97.
Riwayat rasio P/B untuk Synairgen plc dari 2004 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) 0.15 -78.10%
2023 0.69 -29.11%
2022 0.97 -88.10%
2021 8.13 326.23%
2020 1.91 -7.27%
2019 2.06 -99.86%
2018 1.50K 26.76%
2017 1.18K -39.85%
2016 1.97K -1.83%
2015 2.01K -7.72%
2014 2.17K 11,509.79%
2013 18.72 170.50%
2012 6.92 224.88%
2011 2.13 16.99%
2010 1.82 206.96%
2009 0.59 -73.97%
2008 2.28 35.55%
2007 1.68 -99.48%
2006 322.75 18.54%
2005 272.28 1,051.93%
2004 23.64 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 4,043.81%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 4,101.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 2,305.03%
BE